博士（中山大学）

Professor Wenzhao Zhong graduated from Sun Yat-sen University (Ph.D in Thoracic Oncology Surgery) in 2007. He is currently the chief physician, the deputy director of the Guangdong Lung Cancer Institute, a doctoral Supervisor at the Medical College of South China University of Technology and Southern Medical University. His academic part-time job includes director of the Chinese Society of Clinical Oncology, deputy chairman of the Committee of Young Experts, leader of the lung cancer specialty, judge of the National Natural Science Foundation of China, deputy leader of the Cancer Early Diagnosis and Treatment Group of Chinese Medical Association, associate Editor of the Official Journal of the International Association for the Study of Lung Cance(J Thorac Oncol, IF=12.46), deputy Chairman of the Lung Oncology Branch of Guangdong Medical Association.
Professor Zhong mainly engaged in lung cancer surgery-oriented single disease multidisciplinary comprehensive treatment, including stage IIIA-N2 Lung Cancer, classification diagnosis and treatment of solitary pulmonary nodule/adenocarcinoma of lung/GGO, minimally invasive thoracoscopic radical resection of lung cancer, pathological classification of lung cancer and clinical practice, artificial intelligence image-liquid biopsy for lung cancer and early screening and diagnosis system, etc. He has undertaken four research projects supported by the National Natural Science Foundation of China. The research results published more than 40 papers in journals like Lancet oncol(IF=35.386)，J Clin Oncol(IF=28.245)*2，J Thorac Oncol(IF=12.46)*6，J Extracell Vesicles(IF=11), etc. He received the awards include the second prize of National Science and Technology Progress Award (2018), the first prize of China Medical Science and Technology Award (2016), the first prize of Guangdong Science and Technology Award (2010, 2013), the second prize of Guangdong Science and Technology Award (2016).

1. Wen-Zhao Zhong#, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-Long Wu*, on behalf of the ADJUVANT investigators; Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study, The Lancet Oncology, 2018, 19(1):139-148. (IF=35.386)
2. Wen-Zhao Zhong#, Si-Yang Liu, Yi-Long Wu*; Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, 2017, 35(11):1143-1145. (IF=28.245)
3. Wen-Zhao Zhong#, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-zheng Kang, Wan-pu Yan, Hong-Hong Yan, MARi-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Yi-Long Wu*; Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study, Journal of Clinical Oncology, 2019, 37(25):2235-2245. (IF=28.245)
4. Chao Zhang#, Li-Xu Yan, Ben-Yuan Jiang, Yi-Long Wu, Wen-Zhao Zhong*; Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC, Journal of Thoracic Oncology, 2020, 15(6):e95-e99.. (IF=12.46)
5. Huan Lin#, Wen-Zhao Zhong#, Xue-Ning Yang, Xu-Chao Zhang, Jin-Ji Yang, Qing Zhou, Hong-Hong Yan, Ri-Qiang Liao, Qiang Nie, Song Dong, Yi-Long Wu*; A Clinical Model to Estimate the Pretest Probability of Lung Cancer, Based on 1198 Pedigrees in China, Journal of Thoracic Oncology, 2012, 7(10):1534-40. (IF=12.46)
6. Chao Zhang#, Shao-lei Li#, Qiang Nie, Song Dong, Yang Shao, Xue-ning Yang, Yi-long Wu, Yue Yang, Wen-zhao Zhong*; Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement, Journal of Thoracic Oncology, 2019, 14(4):726-731. (IF=12.46)
7. Song-Tao Xu#, Jun-Jie Xi#, Wen-Zhao Zhong#, Wei-Min Mao, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen,  Shi-Dong Xu, Lun-Xu Liu, Ping Yu,  Bu-Hai Wang, Hai-Tao M  Hong-Hong Yan, BS, Xue-Ning Yang, Yong-Xing Zhang, Jia-Cheng Yin, BS, Qun Wang, Yi-Long Wu*; The unique spatial–temporal treatment failure patterns of adjuvant gefitinib therapy: A post-hoc analysis of the ADJUVANT trial (CTONG 1104), Journal of Thoracic Oncology, 2019, 14(3):503-512. (IF=12.46)
8. Chao Zhang#, Jianjun Zhang#, Fang-Ping Xu, Yin-Guang Wang, Zhi Xie, Jian Su, Song Dong, Qiang Nie, Yang Shao, Qing Zhou, Jin-Ji Yang, Xue-Ning Yang, Xu-Chao Zhang, Zhi Li, Yi-Long Wu, Wen-Zhao Zhong*; Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma, Journal of Thoracic Oncology, 2019, 14(11):1912-1923. (IF=12.46)
9. Chao Zhang#, Yi-Long Wu, Wen-Zhao Zhong*; Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib, Journal of Thoracic Oncology, 2019, 14(10):e234-e236. (IF=12.46)
10. Jia-Tao Zhang#, Hao Qin, Fiona Ka Man Cheung, Jian Su, Da-Dong Zhang, Shi-Yi Liu, Xiao-Fang Li, Jing Qin, Jun-Tao Lin, Ben-Yuan Jiang, Song Dong, Ri-Qiang Liao, Nie Qiang, Xue-Ning Yang, Hai-Yan Tu, Qing Zhou, Jin-Ji Yang, Xu-Chao Zhang, Ya-Nan Zhang, Yi-Long Wu*, Wen-Zhao Zhong*; Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules, Journal of Extracellular Vesicles, 2019, 8(1):1663666. (IF=11)